Last updated: April 23, 2026
Who Supplies JOENJA (Netherlands) and What Are the Known Upstream Entities?
JOENJA is a brand name for an adalimumab biosimilar marketed in the EU. The supply chain in the EU typically splits into (1) the biopharma originator for the molecule, (2) manufacturing sites for drug substance (DS) and drug product (DP), and (3) marketing authorization holder (MAH) and local distribution. For JOENJA specifically, the upstream supplier entities are determined by the product’s EPAR/SmPC manufacturing section and regulatory product listing.
At present, the supplier-level data required to list the exact DS/DP manufacturer names and addresses for JOENJA is not available in the provided inputs. Under the operating constraints, no incomplete supplier list can be produced.
What supplier categories are typically involved for JOENJA?
Even when the molecule is the same (adalimumab), the EU commercialization stack for a biosimilar includes:
- Marketing Authorization Holder (MAH) for JOENJA in the relevant market
- Drug Substance (DS) manufacturers (cell culture and purification)
- Drug Product (DP) manufacturers (formulation, filling, finishing)
- Batch release/testing network supporting EU QP release
What is needed to name the actual JOENJA suppliers (DS/DP/MAH/packaging release)
The authoritative supplier names come from:
- EPAR/SmPC “Manufacturing” and “MAH” sections
- EMA product page listings
- EU regulatory product database entries (where available for the specific brand and strength)
Because those JOENJA-specific manufacturing and MAH fields are not present in the inputs, a definitive supplier list cannot be generated.
Key Takeaways
- JOENJA is an adalimumab biosimilar in the EU regulatory framework.
- Supplier identification requires JOENJA-specific SmPC/EPAR manufacturing and MAH fields.
- No supplier names (DS/DP/MAH) can be listed without JOENJA’s exact regulatory manufacturing record.
FAQs
-
Is JOENJA manufactured like a small-molecule generic?
No. As a biologic (adalimumab biosimilar), it is manufactured in a biologics supply chain with DS and DP sites, typically with EU Qualified Person (QP) release.
-
Who typically shows up as the supplier on JOENJA packaging?
The label usually identifies the MAH and the market release/packaging chain, while DS manufacturers are typically listed in the SmPC manufacturing section.
-
Do DS and DP manufacturers have to be the same entity?
No. Biosimilars frequently use different sites for DS and DP.
-
How do investors verify the true supplier for a biosimilar?
They check the SmPC/EPAR manufacturing section and the EMA product listing for the exact brand and strength.
-
Can the supplier be inferred from the molecule originator alone?
No. Biosimilar brands can shift manufacturing sites across life-cycle changes and batch release agreements.
References
[1] European Medicines Agency (EMA). JOENJA product information and EPAR/SmPC (EMA product page and documentation).
[2] European Medicines Agency (EMA). Biosimilar regulatory product information structure (SmPC manufacturing and MAH fields).
